TORONTO, ONTARIO--(Marketwire - July 8, 2008) - PharmEng International Inc. (“PharmEng”) (TSX VENTURE:PII), today announced that its wholly owned subsidiary, Keata Pharma Inc. (“Keata”), received a drug establishment license on June 26, 2008 for its manufacturing facility located in Sydney, Nova Scotia. The establishment license was issued after a Good Manufacturing Practices (GMP) inspection was conducted under the authority of the Food and Drugs Act to verify compliance with the applicable regulations. The inspection concluded favourably on June 13,2008. The establishment license is for the manufacturing, testing and packaging of the following drug dosage forms; capsules, powders, solutions and tablets.
